| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-09-03 | Genenta Science (Italy) | nomination |
Cancer - Oncology - Rare diseases | Nomination | ||
| 2015-09-03 | Serodus (Norway) | nomination |
Cardiovascular diseases - Metabolic diseases | Nomination | ||
| 2015-09-02 | Shire (UK) Sangamo BioSciences (USA) | therapeutics based on Sangamo’s zinc finger DNA-binding protein (ZFP) technology | hemophilia A, hemophilia B, Huntington's disease and other monogenic diseases | collaboration |
Hematological diseases - Genetic diseases | Licensing agreement |
| 2015-09-02 | Evotec (Germany) CHDI Foundation (USA - NY) | Huntington’s disease | collaboration |
Genetic diseases - Neurodegenerative diseases - Rare diseases | Collaboration agreement | |
| 2015-09-02 | Incyte (USA - DE) Jiangsu Hengrui Medicine (China) | SHR-1210 | advanced solid tumors | development licensing commercialisation |
Cancer - Oncology | Licensing agreement |
| 2015-09-02 | AstraZeneca (UK) Daiichi Sankyo (Japan) | FluMist® Quadrivalent | influenza | development commercialisation |
Infectious diseases | Development agreement |
| 2015-09-02 | Summit Therapeutics (UK) | nomination |
Infectious diseases - Neuromuscular diseases - Rare diseases | Nomination | ||
| 2015-09-02 | AmpliPhi BioSciences (USA - VA) | nomination |
Infectious diseases | Nomination | ||
| 2015-09-02 | Therametrics (Switzerland) Accelovance (USA - MD) | collaboration clinical research |
Technology - Services | Collaboration agreement | ||
| 2015-09-02 | Sumitomo Dainippon Pharma (Japan) Exscientia (UK) | research - R&D | Mental diseases - Psychiatric diseases | Milestone | ||
| 2015-09-02 | Pieris (Germany) | establishment of a new subsidiary in the US - nomination | Establishment of a new subsidiary in the US | |||
| 2015-09-01 | Ardelyx (USA - CA) Sanofi (France) | phosphate transport NaP2b inhibitor program (also known as NaPi2b, Npt2b and SLC34A2) | termination of a licensing agreement |
Renal diseases - Kidney diseases | Termination of an agreement | |
| 2015-09-01 | BergenBio (Norway) | nomination |
Nomination | |||
| 2015-09-01 | Shire (UK - USA) | nomination |
Rare diseases - Genetic diseases | Nomination | ||
| 2015-09-01 | Erytech Pharma (France) | nomination |
Cancer - Oncology - Rare diseases | Nomination | ||
| 2015-09-01 | Ose Pharma (France) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-09-01 | Neurovive Pharmaceutical (Sweden) | resignation |
Resignation | |||
| 2015-08-31 | Diamyd Medical (Sweden) Professor Karsten Buschard (Denmark) | drug candidate based on gliadin | type 1 diabetes, gluten intolerance (celiac disease) and other inflammatory diseases | licensing |
Autoimmune diseases – Inflammatory diseases - Immunological diseases | Licensing agreement |
| 2015-08-31 | Iteos Therapeutics (Belgium) Pfizer (USA - NY) | pre-clinical compounds targeting Indoleamine 2,3-dioxygenase (IDO1) and Tryptophan 2,3-dioxygenase (TDO2) | licensing collaboration |
Cancer - Oncology | Licensing agreement | |
| 2015-08-31 | Celyad previously known as Cardio3 Biosciences (Belgium) Medisun International Limited (China) | C-Cure® | licensing disribution collaboration |
Licensing agreement |
